How has been the historical performance of Rossari Biotech?

Answer:The historical performance of Rossari Biotech shows significant growth in net sales and profits over the years, with net sales increasing from 600.09 Cr in March 2020 to 2,080.29 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,080.29 Cr in March 2025, compared to 600.09 Cr in March 2020. Operating profit (PBDIT) also rose from 108.46 Cr in March 2020 to 269.08 Cr in March 2025, reflecting a consistent increase in profitability. The profit after tax grew from 65.47 Cr in March 2020 to 135.40 Cr in March 2025, indicating a healthy growth trajectory. The company's total assets increased from 471.46 Cr in March 2020 to 1,885.67 Cr in March 2025, while total liabilities rose from 471.46 Cr to 1,885.67 Cr in the same period, suggesting a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 137.00 Cr in March 2025, compared to 56.00 Cr in March 2020, while the net cash inflow turned positive at 19.00 Cr in March 2025, contrasting with a net outflow of 14.00 Cr in March 2021.

Breakdown:
Rossari Biotech has demonstrated robust growth in its financial performance over the years. Net sales surged from 600.09 Cr in March 2020 to 2,080.29 Cr in March 2025, while total operating income mirrored this growth, reaching the same figure. The operating profit (PBDIT) increased from 108.46 Cr to 269.08 Cr, showcasing enhanced profitability. Profit after tax also saw a significant rise from 65.47 Cr to 135.40 Cr, reflecting the company's strong earnings growth. On the balance sheet, total assets expanded from 471.46 Cr to 1,885.67 Cr, with total liabilities increasing correspondingly, indicating a balanced growth in financial structure. Cash flow from operating activities improved markedly, reaching 137.00 Cr in March 2025, and the company achieved a positive net cash inflow of 19.00 Cr, reversing previous outflows, which highlights its strengthening cash position.